Pliant Therapeutics
PLRX
37 hedge funds and large institutions have $877M invested in Pliant Therapeutics in 2020 Q2 according to their latest regulatory filings, with 37 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
79.7% more ownership
Funds ownership: 0% → 79.7% (+80%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP III
Boston,
Massachusetts
|
+$155M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$142M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$90.5M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$75.3M |
| 5 |
CA
CHI Advisors
New York
|
+$61.2M |
Top Sellers
PLRX Hedge Fund Activity: Q2 2020 in Review
37 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q2 2020, worth a combined $877M.
Buyers outnumbered sellers: 37 funds opened new PLRX positions and 0 closed out — a net gain of 37 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was TRV GP III, opening a new position worth an estimated $155M.
- 37 institutional investors held Pliant Therapeutics (PLRX) as of Q2 2020, up from 0 in Q1 2020.
- Funds reported $877M of Pliant Therapeutics stock for Q2 2020.
- 37 funds opened new Pliant Therapeutics positions in Q2 2020 and 0 closed out, a net change of +37 holders.
- The largest Pliant Therapeutics buyer in Q2 2020 was TRV GP III, an estimated $155M added.
Based on aggregated 13F filings for Q2 2020.